Anhedonia · Treatment evidence, November 2026

Anhedonia Treatment: What Helps, What the Studies Show, and What Failed in 2026

Anhedonia is the loss of pleasure or interest in things that used to matter. No medicine is approved for it alone, but therapy, some antidepressants, esketamine and TMS have each improved it in studies. Here is what each one showed, with the numbers, and where to start.

TMS therapy in Cranford

In a crisis, call or text 988, 24/7. If someone is in immediate danger, call 911.

Labyrinth Psychiatry Group · Published · Clinical review by Dr. Salvatore G. Savatta pending · Sources read

35% to 70%The share of people with major depression who have anhedonia, across studies (Al-Soleiti 2025).
At most halfThe chance of remission on an antidepressant for people with the most loss of interest, against those with the least (Uher 2012, 4,448 patients).
56%Clinic patients no longer anhedonic after a standard TMS course, up from 8% before (Fukuda 2021, 105 patients).
38%Patients with treatment-resistant depression whose anhedonia score halved by three months on esketamine nasal spray (REAL-ESK, 199 patients).

The short answer

There is no single treatment for anhedonia, and no medicine is approved for it alone. A 2025 review in the journal Brain puts it plainly: “Currently, there is no FDA-approved treatment specifically targeting anhedonia.” Cleveland Clinic says clinicians treat it by “diagnosing and treating the cause or underlying condition,” such as depression.

What the studies support, in brief:

  • Talk therapy that rebuilds activity and reward. In a 440-patient trial, CBT and behavioral activation both improved anhedonia, but only partly (COBRA).
  • A different antidepressant. A 2025 review rates SSRIs as less effective for anhedonia than vortioxetine, bupropion and some others (Serretti).
  • Ketamine and esketamine. One ketamine infusion rapidly reduced anhedonia in a placebo-controlled study (Lally 2014). On esketamine nasal spray (SPRAVATO), 38% of 199 patients with treatment-resistant depression had their anhedonia score halved by three months (REAL-ESK).
  • TMS. In one clinic, 79% of patients had severe anhedonia before a standard TMS course. Afterward, 56% were no longer anhedonic (Fukuda 2021).
  • Not yet: a pill for anhedonia itself. Two late-stage drugs from a class studied for anhedonia were stopped in phase 3 depression trials, in March 2025 and June 2026.

If you have lost interest or pleasure in most things, most of the day, nearly every day, for at least two weeks, that is one of the two core symptoms of depression (NIMH). Have it evaluated. In Cleveland Clinic’s words, anhedonia “doesn’t go away on its own.”

A wooden footbridge over the lake in Nomahegan Park in Cranford, with white flowering trees on the far bank
Nomahegan Park in Cranford, Union County, the town of Labyrinth’s Cranford office. Photo: CC0, via Wikimedia Commons.

What anhedonia is, and what it is not

Cleveland Clinic defines anhedonia as “the inability to experience joy or pleasure.” The term was introduced in 1896 by the French psychologist Théodule-Armand Ribot (Al-Soleiti 2025). Today it is one of two core symptoms of depression: NIMH says a diagnosis requires either a depressed mood or “a loss of interest or pleasure in most activities.”

Researchers divide anhedonia into parts. A 2025 review says the key to choosing a treatment is to identify those parts “as accurately as possible” (Pelc 2025):

  • Anticipatory: little joy in looking forward to things, and trouble imagining pleasant experiences (Pelc).
  • Motivational: low willingness to start activities that would be rewarding (Pelc).
  • Consummatory: less pleasure during the activity itself (Pelc).
  • Social: not enjoying time with other people (Cleveland Clinic).
  • Physical: touch, smells, sounds, food or sex no longer bring joy (Cleveland Clinic).

Two look-alikes are worth separating. Apathy is “a lack of energy or motivation to do things,” while anhedonia is “the lack of enjoyment or pleasure” (Cleveland Clinic). Fatigue is different again. Pelc and colleagues suggest one question: once you have started an activity, do you feel pleasure? If not, anhedonia is the more likely problem. If you do, but a lack of strength keeps you from starting, fatigue is.

How it can feel, in Cleveland Clinic’s description: an emptiness “where you expect your feelings to be,” with numbness, boredom, apathy or negativity. Sleep, sex drive and time with people can all suffer.

Depression is one cause, but not the only one. Cleveland Clinic also lists schizophrenia, bipolar disorder, substance use disorder, Parkinson’s disease, post-traumatic stress disorder and traumatic brain injury. Anhedonia can also be a side effect of some medicines, such as dopamine blockers (Al-Soleiti). NIMH notes that certain medicines and medical conditions, such as thyroid disorders, can cause the same symptoms as depression. That is why an evaluation starts with the full picture.

Why anhedonia is harder to treat than low mood

  • It predicts a weaker response to antidepressants. In two large studies, 811 adults on escitalopram or nortriptyline and 3,637 on citalopram, people in the top fifth for loss of interest, activity and enjoyment had at most half the chance of remission of those in the bottom fifth (Uher 2012).
  • It is often the last symptom to lift. In an open-label study of 140 patients on sertraline, anxiety improved first (days 0 to 7), other depressive symptoms next (days 7 to 21) and anhedonia last (days 21 to 56), as summarized by Serretti.
  • Standard treatment can blunt reward. NIMH researchers wrote that standard depression treatments “do little to alleviate the symptoms of anhedonia and may cause reward blunting” (Lally 2014).
  • It slows recovery from depression. In the COBRA trial, more anhedonia at the start predicted less recovery from depression and fewer depression-free days (Alsayednasser 2022).
  • It is linked to suicidal thinking. In an inpatient sample of 1,529 people, anhedonia predicted suicidal ideation, and changes in anhedonia tracked changes in suicidality (Al-Soleiti). If you have thoughts of death, call or text 988 now.

Anhedonia treatments compared

Each row is what the named study or review found, read on November 17, 2026. The last column says only what the practice’s own pages state.

Anhedonia treatments: what the studies found, their limits, and what Labyrinth offers
TreatmentWhat the studies foundSize and limitsAt Labyrinth
CBT and behavioral activation (talk therapy)Both improved anhedonia over six months of treatment, with no difference between them. The gain was smaller than the gain in depression (COBRA).440 adults with major depression. Anhedonia was still above healthy averages at six months and did not improve further at 12 or 18 months.The practice’s therapists list cognitive-behavioral therapy and mindfulness-based approaches among their therapies, for adults, in person or virtually.
Reward-focused therapy (for example, positive affect treatment)Built to increase positive emotion, not only to reduce negative emotion. Newer approaches “show preliminary efficacy” (Sandman and Craske).Less tested than CBT. The same review calls most psychological interventions “largely ineffective for reducing anhedonia.”Not named on the practice’s list of therapies. Ask at the evaluation.
A different antidepressantSSRIs, and to a lesser degree SNRIs, look less effective for anhedonia. Vortioxetine, bupropion and brexpiprazole look more promising (Serretti). In 11 pooled trials, vortioxetine improved anhedonia more at higher doses.The vortioxetine results come from post hoc analyses. Bupropion’s studies had smaller samples (Al-Soleiti). None of these medicines is approved for anhedonia itself.Medication management with the practice’s psychiatrists and nurse practitioners.
Ketamine infusionOne infusion rapidly reduced anhedonia, separately from other depressive symptoms, in a placebo-controlled crossover study (Lally).36 patients, all with treatment-resistant bipolar depression, one dose. A 2025 review notes acute side effects and an unknown long-term safety profile (Costi).This site does not describe ketamine infusions. Ask at the evaluation.
Esketamine nasal spray (SPRAVATO)38% of 199 patients with treatment-resistant depression had their anhedonia score cut at least in half by three months, separately from overall improvement (REAL-ESK).Observational, with no placebo group; 14% stopped early. Several authors reported fees from Janssen and other drug companies.Given in Cranford for adults whose depression has not improved enough with antidepressants. At least 2 hours of observation; no driving until the next day.
TMS (transcranial magnetic stimulation)Among 105 clinic patients, severe anhedonia fell from 79% before a standard course to 22% after, and 56% were no longer anhedonic (Fukuda).One clinic, no sham group. With a different target and 20 sessions, high anhedonia went with non-response (Downar).In Cranford: 36 sessions for depression, five days a week, about six to eight weeks. No anesthesia; you can drive yourself.
Exercise and daily activityLifestyle factors, including exercise, “may exert subtle but meaningful influences” on anhedonia (Serretti). Cleveland Clinic lists regular exercise.The effect “can vary based on individual patient characteristics and baseline conditions” (Serretti).Lifestyle changes are on the practice’s list of what a depression treatment plan may include.
Kappa-opioid blockers (aticaprant, navacaprant)Stopped in phase 3 depression trials. A J&J trial in depression with moderate-to-severe anhedonia ended for “insufficient efficacy.” Neumora’s two latest phase 3 trials missed their main goal.J&J ended aticaprant’s phase 3 depression program in March 2025 and said it would explore other areas for the drug; Neumora discontinued navacaprant in June 2026.Not a treatment option.

Sources for the table: COBRA, Sandman and Craske, Serretti, Al-Soleiti, Lally, Costi, REAL-ESK, Fukuda, Downar, Cleveland Clinic, ClinicalTrials.gov, Fierce Biotech and Neumora. Practice column: the psychotherapy, medication management, SPRAVATO, TMS and depression and anxiety pages.

Therapy for anhedonia

Most talk therapy for depression was built to reduce negative feelings, not to bring back positive ones. A review by Christina Sandman and Michelle Craske says most psychological interventions are designed to decrease negative affect rather than increase positive affect, and “are largely ineffective for reducing anhedonia” (Sandman and Craske 2022). Newer approaches aim at reward directly: looking forward to things, responding to them, and learning from them. Those “show preliminary efficacy.”

The largest test of standard therapy here is the COBRA trial. It assigned 440 adults with major depression to cognitive behavioral therapy (CBT) or to behavioral activation, which rebuilds rewarding activity step by step (Alsayednasser 2022):

  • Both therapies improved anhedonia during six months of treatment, with no significant difference between them.
  • Anhedonia improved less than depression did in both groups.
  • At six months, participants were still above healthy averages for anhedonia, and there was no further improvement at 12 or 18 months.
  • The authors’ conclusion: both are “similarly and only partially effective in treating anhedonia.”
The Rahway River in Cranford on a summer day, with green trees on both banks reflected in still water
The Rahway River in Cranford. Behavioral activation rebuilds rewarding activity step by step. Photo: CC0, via Wikimedia Commons.

The approaches reviewers single out for anhedonia are behavioral activation, mindfulness-based strategies and savoring, which “help re-engage patients with pleasurable activities and enhance positive affect” (Serretti). Al-Soleiti adds positive affect treatment to the list of the most studied.

At Labyrinth, therapists list cognitive-behavioral therapy, mindfulness-based meditation approaches, interpersonal therapy, psychodynamic therapy and DBT-informed therapy among the therapies they provide, for adults 18 and older, in person or virtually. Each person referred for therapy has a full assessment first. If you are seeking help for anhedonia, say so at the start, and ask how the plan will rebuild activity and enjoyment. Read more on the psychotherapy page.

Medication for anhedonia

No medicine is approved for anhedonia itself, so prescribers choose among medicines used for depression. The evidence on which ones help anhedonia most comes mainly from reviews and secondary analyses:

  • SSRIs and SNRIs. Traditional antidepressants such as SNRIs “and, even more so,” SSRIs “are less effective” for anhedonia (Serretti 2025).
  • Vortioxetine. A pooled analysis of 11 short-term, placebo-controlled trials, with 3,219 patients on vortioxetine and 1,769 on placebo, found that it improved anhedonia, more so at higher doses (Serretti).
  • Bupropion. It “was shown to have good efficacy in treating anhedonia,” though “the studies had smaller samples” (Al-Soleiti 2025).
  • Brexpiprazole. Serretti lists it among drugs with “promising anti-anhedonic effects.”

If you feel flat or numb on your current medicine, tell your prescriber rather than stopping on your own. At Labyrinth, medication management visits with the practice’s psychiatrists and nurse practitioners review benefit, side effects, history and goals, with monitoring and follow-up. If two or more antidepressants have not helped enough, read about treatment-resistant depression, where the next options include TMS and SPRAVATO.

Ketamine and SPRAVATO (esketamine) for anhedonia

A 2025 review in Brain says ketamine “alleviates depressive symptoms, including the difficult-to-treat symptom of anhedonia, within hours.” The studies behind that, and the related nasal spray:

  • A single ketamine infusion. In a placebo-controlled crossover study at NIMH, ketamine “rapidly reduced the levels of anhedonia” in 36 patients with treatment-resistant bipolar depression, independently of other depressive symptoms (Lally 2014).
  • Esketamine nasal spray, real-world use. The REAL-ESK study followed 253 patients given repeated esketamine nasal spray with their current medicines. Among the 199 with treatment-resistant depression, 38% had their anhedonia score cut at least in half by three months, and 14% dropped out, mostly for lack of effect or side effects. The authors found the effect on anhedonia distinct from the overall improvement in depression (d’Andrea 2025).
  • The comparison. A 2025 review found esketamine effective for anhedonia, “albeit to a lesser extent than racemic ketamine” (Al-Soleiti).

Two limits apply. REAL-ESK had no placebo group, and several of its authors reported fees from Janssen and other drug companies. The ketamine study tested one dose in a small bipolar group. The Brain review adds that ketamine’s clinical application “is constrained by acute side effects and an unknown long-term safety profile.”

Labyrinth gives SPRAVATO in Cranford, for adults whose depression has not improved enough with antidepressants. As the practice’s SPRAVATO page describes it:

  • You take the nasal spray yourself in the office while a clinician watches, then stay for at least two hours of observation.
  • You need a ride home and cannot drive until the next day.
  • Weeks 1 to 4: two visits a week. Weeks 5 to 8: one a week. From week 9: one visit a week or every two weeks.
  • SPRAVATO is given only through an FDA-required safety program, the SPRAVATO REMS; the office completes the enrollment with you.
  • The office handles insurance approval, which usually takes 1 to 4 weeks from the first call to the first treatment.

TMS for anhedonia

The first large study of everyday, non-research TMS and anhedonia, in its authors’ description, comes from the Butler Hospital TMS Clinic in Providence, Rhode Island (Fukuda 2021). It followed 144 patients through their first standard course: TMS over the left front of the brain (the left dorsolateral prefrontal cortex), mostly at 10 Hz, for an average of about 35 sessions. Anhedonia was scored on the Snaith-Hamilton Pleasure Scale.

Anhedonia before and after a standard TMS course in the 105 clinic patients with both scores (Fukuda et al., 2021). Before: 8% not anhedonic, 13% mild or moderate, 79% severe. After: 56% not anhedonic, 22% mild or moderate, 22% severe.
Snaith-Hamilton Pleasure Scale groups, 105 patients (Fukuda et al., Brain and Behavior, 2021)
WhenNot anhedonicMild or moderateSeverePatients (not / mild or moderate / severe)
Before TMS7.62%13.33%79.05%8 / 14 / 83
After TMS56.19%21.90%21.90%59 / 23 / 23
  • The average anhedonia score fell from 8.10 to 3.06, an average drop of 58.55%, among the 105 patients scored before and after.
  • Across all 144 patients, 45.83% responded and 31.94% reached remission on the depression scale used (IDS-SR).
  • Patients with severe anhedonia at the start “had an equal chance of achieving clinical response/remission.” The authors’ advice: people with anhedonia “should not be excluded from treatment” if they are otherwise suitable.

A 2025 review adds a head-to-head result. In 89 patients with moderately treatment-resistant depression, rTMS “showed superior improvements in anhedonia” compared with switching antidepressants (Serretti).

The target matters. In a Toronto study of 47 patients given 20 sessions over a different area (the dorsomedial prefrontal cortex), people who did not respond had markedly higher anhedonia at the start (Downar 2014). Fukuda’s team notes that most American TMS clinicians do not routinely stimulate that area, and that 30 or more sessions are delivered in a typical course in the United States. The Butler study had no sham group, so it shows what happened in practice, not what TMS adds over placebo.

At Labyrinth, TMS in Cranford is for depression that medication has not relieved, and for OCD. A standard course for depression is 36 sessions, five days a week, which takes about six to eight weeks. Each session lasts 19 to 45 minutes. There is no anesthesia, and you can drive yourself. Which protocol fits you is decided at the evaluation. For response and remission figures across the major TMS trials, see TMS success rate, and for a side-by-side of the two treatments, TMS vs. SPRAVATO.

What failed: two kappa-opioid drugs stopped in phase 3 depression trials in 2025 and 2026

Reviewers had named one drug class, the kappa-opioid receptor antagonists, among the options that “offer great hope” for anhedonia (Pelc 2025). An early proof-of-mechanism trial of one of them, aticaprant, enrolled 89 participants with clinically significant anhedonia (Serretti). Two drugs from the class reached phase 3 trials in depression, and both depression programs have now stopped:

  • Aticaprant (Johnson & Johnson), March 2025. J&J stopped its phase 3 program “because of insufficient efficacy in the target patient population” (Fierce Biotech). Its relapse-prevention trial, VENTURA-5, studied add-on aticaprant in major depression “with moderate-to-severe anhedonia.” ClinicalTrials.gov lists it as terminated “due to insufficient efficacy” (NCT06635135). J&J said it would “explore future development opportunities for aticaprant in other areas of high unmet need” (Fierce Biotech).
  • Navacaprant (Neumora), June 15, 2026. Two phase 3 trials in major depression, KOASTAL-2 with 430 adults and KOASTAL-3 with 422, “did not achieve statistical significance on the primary or key secondary endpoints.” The company “is discontinuing development of navacaprant” (Neumora SEC filing). An earlier phase 3 trial had failed in January 2025 (Fierce Biotech).

For patients, the meaning is practical. The treatments with anhedonia data today are the ones already in use: therapy, a review of antidepressants, esketamine and TMS.

Can GLP-1 medicines cause anhedonia?

This is a common question from people taking GLP-1 medicines for weight or diabetes. The short answer: the evidence does not show it, but it has not been studied well.

  • The overall picture. “Studies to date have not found convincing evidence that GLP-1 medications cause anhedonia,” according to an August 2026 article from MUSC Health, the Medical University of South Carolina. It adds that the evidence on anhedonia specifically “is much thinner,” because most studies were not designed to measure it (MUSC Health).
  • Case reports. A 2026 series described three women on high-dose tirzepatide (15 mg a week) who reported reduced motivation, emotional “flatness” or loss of interest. After their doses were lowered to 10 mg a week or less, two improved markedly, and one also needed bupropion (Nadolsky 2026). Three patients and no comparison group cannot show cause.

If you have noticed this on a GLP-1 medicine, tell the clinician who prescribes it. If you also see a psychiatrist, tell them too, so the two can look at the whole picture.

Is anhedonia permanent?

Not usually. Cleveland Clinic says it “can go away or get better under the supervision of a healthcare provider and/or a mental health professional.” It also says anhedonia “may come back after treatment,” and that following the treatment plan, “even if you feel better,” lowers that risk.

The studies above show both sides. After TMS, 56% of clinic patients were no longer anhedonic (Fukuda). After therapy, anhedonia improved but stayed above healthy averages at six months (COBRA). Improvement is common in these studies; for some people it is partial, and a second approach is part of the plan.

When it is time to be evaluated

None of these signs is a diagnosis. Each is a reason to see a clinician rather than wait:

  • It has lasted two weeks or more. Loss of interest or pleasure most of the day, nearly every day, for at least two weeks is NIMH’s threshold for depression.
  • It is getting in the way of work, school, relationships or caring for yourself.
  • Antidepressants have not brought it back. If you have tried two or more without enough relief, a treatment-resistant depression evaluation looks at what has been tried and what comes next.
  • It started after a new medicine, including a GLP-1 medicine. NIMH notes that medicines taken for an illness can cause side effects that contribute to depression symptoms. Tell the prescriber.
  • There are other changes, such as more drinking or drug use, a stretch of unusually elevated mood or activity, or hallucinations. NIMH lists these with depression and the conditions related to it.
  • You have thoughts of death or suicide. Do not wait for an appointment. Call or text 988 now, or call 911 if someone is in immediate danger.

Getting anhedonia treated in Cranford and Edison

Two of the treatments with the most anhedonia data are in person and frequent. TMS at Labyrinth is 36 sessions for depression, five days a week. SPRAVATO is taken in the office twice a week for the first four weeks, each time with at least two hours of observation and a ride home. A treatment like that has to be close to home or work.

Labyrinth Psychiatry Group provides both at 11 Commerce Drive, Lobby Floor, in Cranford, in Union County. Its second office, at 1 Ethel Road, Suite 103B, in Edison, is opening soon, and the practice is already scheduling patients there for the new year.

Amboy Avenue in Edison, New Jersey, a two-lane street with shops, street lamps and white flowering trees
Amboy Avenue in Edison. The practice’s Edison office is at 1 Ethel Road; this photo is of the town, not the office. Photo: CC0, via Wikimedia Commons.

The first visit is an evaluation, not a treatment decision. As the treatment-resistant depression page describes it, the evaluation covers four things:

  • Treatment history: what you have tried, for how long, what changed, and what made a treatment hard to continue.
  • The broader picture: mood, anxiety, sleep, attention, trauma, substance use, medical factors and other conditions.
  • Safety and fit: clinical eligibility, contraindications, current risk, treatment setting, transportation, schedule and insurance access.
  • Your priorities: past side effects, time demands, preferences, work and caregiving needs, and what progress would mean to you.

It helps to bring a list of every antidepressant you have taken, with the dose and how long, and any therapy you have had. Labyrinth provides adult psychiatric care. Call 908-336-1187 or use the appointment request form, and office staff arrange a time with you.

Questions people ask about anhedonia treatment

What is the best treatment for anhedonia?

There is no single best one, because anhedonia is a symptom with several possible causes. Cleveland Clinic says it is treated by diagnosing and treating the underlying condition. In studies, talk therapy helped partly, some antidepressants did better than SSRIs, ketamine and esketamine acted quickly, and TMS improved it in clinic patients. Which fits you depends on what you have already tried, your safety and your schedule, and is decided at an evaluation.

Can anhedonia be cured?

It can improve. Cleveland Clinic says anhedonia “can go away or get better” with a healthcare provider or mental health professional, that it “doesn’t go away on its own,” and that it may come back after treatment. In one clinic study, 56% of patients with a before-and-after score were no longer anhedonic after a course of TMS.

What medication is used for anhedonia?

No medicine is FDA-approved for anhedonia itself (Costi et al., Brain, 2025). Clinicians use medicines approved for depression. Reviews rate SSRIs as less effective for anhedonia, and vortioxetine, bupropion and brexpiprazole as more promising. Esketamine nasal spray (SPRAVATO) is FDA-approved for treatment-resistant depression, and it reduced anhedonia in a 2025 real-world study.

Does bupropion help anhedonia?

A 2025 review says bupropion “was shown to have good efficacy in treating anhedonia, mostly attributed to its role in enhancing reward processing, although the studies had smaller samples.” Whether it suits you depends on your history and your other medicines; ask the prescriber.

Does behavioral activation work for anhedonia?

Partly. In the COBRA trial of 440 adults with major depression, behavioral activation and CBT both improved anhedonia, with no difference between them. The authors concluded that both are “similarly and only partially effective in treating anhedonia.”

Can antidepressants make you feel numb?

NIMH researchers wrote in 2014 that standard depression treatments “do little to alleviate the symptoms of anhedonia and may cause reward blunting.” If you feel flat on a medicine, tell the prescriber. At Labyrinth, medication management visits monitor how a medicine is working and adjust it as needed.

Is anhedonia a sign of depression?

Often, but not always. NIMH says a diagnosis of depression needs either a depressed mood or a loss of interest or pleasure in most activities, most of the day, nearly every day, for at least 2 weeks. Cleveland Clinic lists other conditions that can cause anhedonia, including bipolar disorder, schizophrenia, substance use disorder, PTSD and Parkinson’s disease.

If nothing has felt good for two weeks or more

Start with an evaluation in Cranford.

Appointment requests go through the office, and staff arrange a time with you. The evaluation reviews what you have tried and which options fit, including TMS and SPRAVATO.

Related reading

Treatment-resistant depressionSPRAVATO (esketamine) in CranfordTMS success rate